The FTC press release page on this matter lists the actions and contains links to the case files for each.  Among the cases is one entitled In the Matter of Daniel Chapter One, a corporation, and James Feijo, individually, and as an officer of Daniel Chapter One, Docket No. 9329, File No. 082 3085.

This particular case is worth watching as the respondent, Daniel Chapter One, claims to be a church.  This “healing ministry” follows the “unique principles of BioMolecular Nutrition supplements” used to help “the intense athlete as well as the seriously ill.”

Jim and Trish Fiejo of Daniel Chapter One

Daniel Chapter One founders, Jim and Trish Fiejo, have firmly planted themselves in the center of the “Health Freedom” movement with a Health Freedom Fight website where you can listen to their radio program and contribute to their legal defense by buying a t-shirt.

The Natural Health News has joined in with a piece entitled “Tyrannical FTC Threatens Christian Church with Imprisonment for Selling Dietary Supplements.” Will the FTC be derailed in its efforts to prosecute a supplement company by the First Amendment’s separation of church and state?  Stay tuned…

• None Found

The FTC also announced a new Web site about bogus cancer cures. The site – www.ftc.gov/curious – tells consumers how to spot and report bogus claims they see online, and urges people with cancer to talk to their treatment team about any products they’d like to try.
The site features a video and includes a list of resources on cancer treatments from a variety of agencies within the federal government. Information is provided in English and Spanish.

The cases announced today began through an Internet surf conducted by the FTC, the U.S. Food and Drug Administration (FDA), and Competition Bureau Canada in June 2007. Following the surf, the FTC sent warning letters via e-mail to 112 Web sites between August 2007 and January 2008. Of these, nearly 30 percent either closed their sites or removed the problematic cancer treatment claims. The remainder were reviewed to determine whether a law enforcement action was warranted or whether they should be referred to the FDA or the Competition Bureau.

To read the press release, click here.

• None Found